Mannitol vs. 3% Hypertonic Saline (3% NS) in Pediatric Age

Overview

Mechanisms of Action

Mannitol (20%)

• A simple sugar (osmotic diuretic) that works by two mechanisms:
  1. Rheological effect (immediate, within minutes): Reduces blood viscosity, increases cerebral blood flow (CBF) and O2 delivery, reduces cerebral blood volume and ICP. Adenosine concentration decreases, and CBF is maintained in areas with intact autoregulation.
  2. Osmotic effect (delayed, 20-30 min): Withdraws water from brain parenchyma and excretes it as urine, reducing cerebral edema.
• Eventually enters CSF and can paradoxically increase ICP with prolonged use or repeated dosing ("rebound phenomenon").
• Also a free radical scavenger - contributes to neuroprotection.

3% Hypertonic Saline (HTS)

• Sodium does not cross the intact BBB quickly, maintaining a sustained osmotic gradient (similar in magnitude to mannitol but more prolonged).
• Additional beneficial effects beyond ICP reduction:
  • Enhances cardiac output and increases blood pressure (unlike mannitol, which causes diuresis and can worsen hypotension)
  • Reduces inflammation
  • Restores normal cellular resting membrane potential and cell volume
  • Stimulates release of atrial natriuretic peptide
  • No diuresis - avoids volume depletion
• Miller's Anesthesia, p. 11398-11399

Dosing in Pediatrics

• Rosen's Emergency Medicine, p. 3140; Miller's Anesthesia, p. 11399

Head-to-Head Comparison

Evidence Summary

Meta-Analyses (2023-2026)

• Mortality: No significant difference (RR 0.91; 95% CI 0.54-1.52; p=0.71)
• ICP change at 72h: No significant difference (MD -3.79 mmHg; p=0.46)
• CPP change: No significant difference (MD 4.55 mmHg; p=0.36)
• ICU stay, hospital stay, mechanical ventilation: No significant differences
• Conclusion: Both agents are similarly effective for pediatric ICP management.
• Childs Nerv Syst 2025 (PMID: 41420712)

• ICP reduction by HTS: 17.35 mmHg at 30 min, 9.72 mmHg at 60 min, 8.45 mmHg at 24h (time-dependent pattern)
• Mortality: No significant difference (RR 0.78; 95% CI 0.50-1.23) - high certainty
• Survival rates: Similar (RR 1.05; 95% CI 0.96-1.14)
• HTS adverse effects: Severe hypernatremia (37-53%), AKI (2.1%), ARDS (4.5%)
• Conclusion: Both agents provide comparable ICP reduction and mortality; HTS demonstrates rapid ICP lowering with manageable safety profile.
• Brain Inj 2026 (PMID: 41724523)

• Mortality: No significant difference (RR 1.09; 95% CI 0.74-1.60)
• Serum osmolality: Significantly higher in mannitol group
• Shock and dehydration: Significantly higher in mannitol group
• Hypernatremia: Significantly higher in HTS group
• Overall evidence quality: Low to moderate certainty
• Indian J Pediatr 2023 (PMID: 37225962)

Guideline Positions

• Brain Trauma Foundation (BTF) Pediatric TBI Guidelines 2019: 3% HTS is Grade II evidence for ICP reduction in pediatric TBI. Mannitol use lacks sufficient pediatric-specific data to support it in the same manner.
• Rosen's Emergency Medicine: For suspected acute herniation in children - 3% HTS 2-5 mL/kg over 15 min is recommended; mannitol (0.5-1 g/kg) is used but "data is insufficient in the pediatric population to support its use" as strongly.
• Miller's Anesthesia: A meta-analysis suggests HTS may be superior to mannitol for reducing intracranial hypertension, but large-scale controlled studies are needed.

When to Prefer Each Agent

Prefer 3% Hypertonic Saline:

• Hemodynamically unstable child (hypovolemia, shock) - HTS expands volume while mannitol causes diuresis
• Need for sustained ICP reduction
• Pediatric TBI as first-line hyperosmolar therapy per current guidelines
• Refractory ICP after mannitol failure ("rescue therapy")
• Patient already volume-depleted

Prefer Mannitol or Use Cautiously:

• Hypernatremia already present (sodium >150-155 mEq/L is a contraindication to HTS)
• Child with normal or elevated volume status where diuresis is not harmful
• When free radical scavenging benefit is desired (e.g., post-ischemic injury)
• When HTS is unavailable

Absolute Cautions:

• Both: Do not use when serum osmolality >320 mOsm/L
• Mannitol: Avoid if hypovolemic, hypotensive
• 3% NS: Avoid if serum Na >160 mEq/L or pre-existing severe hypernatremia

Key Practical Points

1. 3% NS is now favored in pediatric practice for acute ICP crises, especially TBI, backed by BTF Grade II evidence.
2. Neither agent has shown superior mortality benefit - the choice is guided by hemodynamics, electrolytes, and clinical context.
3. Monitoring is mandatory: Serum sodium (target 145-155 mEq/L with HTS), serum osmolality (<320 mOsm/L for both), urine output, and renal function.
4. Combination use: Some protocols use mannitol acutely (exploiting the fast rheological effect) and follow with HTS for sustained effect. HTS has also been used as rescue therapy when mannitol fails.
5. Evidence limitations: Most trials are small; high-quality multicenter RCTs in pediatrics remain lacking. The 2026 meta-analysis (Alsabri et al.) calls for standardized protocols and long-term outcome data.